To include your compound in the COVID-19 Resource Center, submit it here.

EMEA requires data from MLNM/ILXO

The EMEA's Committee on Proprietary Medicinal Products (CPMP) recommended approval "under exceptional circumstances" of MLNM and ILXO's MabCampath alemtuzumab

Read the full 191 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE